BioPharma Dive - Latest News

J&J keeps forecasts steady as pharma confronts tariff threat

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its sales guidance for 2025.

Apr 15, 2025 - 16:55
 0
J&J keeps forecasts steady as pharma confronts tariff threat

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its sales guidance for 2025.

Read More

Tags:

Previous Article

Marriott International Expands Presence in India with Debut in Udaipur

Next Article

PSUSA/00002920/202408

Related Posts

RNA editing biotech Airna adds $155M in funding

RNA editing biotech Airna adds $155M in funding

Apr 1, 2025  0

Aardvark prices $94M IPO to fund Prader-Willi, obesity drug work

Aardvark prices $94M IPO to fund Prader-Willi, obesity ...

Feb 13, 2025  0

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Neumora shakes up its C-suite; Biogen cuts early-stage ...

Feb 13, 2025  0